Home or Away From Home - Descriptive Interviews (Aim 2)

Treatment for pediatric acute myeloid leukemia (AML) involves intensive chemotherapy regimens
that result in periods of profound neutropenia leaving patients susceptible to severe
infectious complications. There are little clinical data to inform whether management of
neutropenia post AML chemotherapy should occur in an outpatient or inpatient setting.
Further, no studies have been conducted that assess the impact of neutropenia management
strategy on the quality of life of pediatric patients with AML. Given that infectious
complications are the leading cause of treatment related mortality among AML patients, it is
important to identify the neutropenia management strategy that will lead to the best
clinician- and patient- identified outcomes in order to improve the care of these patients.

This is a qualitative interview study where interviews of patients and/or caregivers will be
performed. Participants will be patients less than 19 years of age at diagnosis (and their
caregivers) receiving or having received chemotherapy for AML from eleven participating
pediatric hospitals across the United States. Participants (children and caregivers) will be
interviewed in an effort to develop a survey that captures patient- and caregiver- identified
outcomes related to neutropenia management.

Inclusion Criteria:

1. To be enrolled in this study, patients must be:

- A male or female between 8 and 22 years of age

- Have a diagnosis of AML

- Be either within 6-12 months of completion of the second course of chemotherapy
for AML OR out of AML therapy for up to 3 years

2. To be enrolled in this study, caregivers must be:

- A male or female 18 years of age or older

- Be the parent/legal guardian of a child that meets the inclusion criteria
detailed above (#1) OR

- Be the parent/legal guardian of a male or female child younger than 8 years of
age with AML and who is within 6-12 months of completion of their second course
of chemotherapy

- Be the parent/legal guardian of a male or female child younger than 8 years of
age with AML and who is out of AML therapy for up to 3 years

3. Parental/guardian informed consent and, if appropriate, child assent.

Exclusion Criteria:

1) None